ONYDA XR (clonidine hydrochloride), a groundbreaking liquid non-stimulant ADHD medication, has been released for commercial availability in the United States. This once-a-day, nighttime medication addresses unmet needs in pediatric ADHD patients aged six and up.
The FDA-approved ONYDA XR is the first liquid non-stimulant ADHD medication in the country and the only non-stimulant option with nighttime administration. Its extended-release profile, made possible by Tris Pharma’s drug-delivery technology, ensures a longer-lasting effect.
With its liquid formulation, ONYDA XR provides an easier and flexible option for administration, allowing patients to adjust dosages as needed. This is especially beneficial for individuals who struggle with pill-swallowing or require a longer-acting therapy.
Tris Pharma’s focus on ADHD, pain, addiction, and neurological disorders has led to the development of ONYDA XR. The company aims to expand access to this innovative treatment and improve the lives of individuals living with ADHD.
ONYDA XR is now available through national pharmaceutical wholesalers, and prescriptions can be filled at local pharmacies across the United States. For more information, healthcare professionals can visit www.onydahcp.com, and patients can explore support options at www.onyda.com.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
